Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

Comprehensive clinical development programs being initiated for each investigational candidate

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year

Astellas completes acquisition of Propella Therapeutics

Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer

AstraZeneca Pharma India receives permission to Import formulations of new drug for sale

The receipt of this permission paves way for the launch of Olaparib film coated tablets in India

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials

Pfizer acquires Seagen for US$ 43 billion to battle cancer

Proposed combination enhances Pfizer’s position as a leading company in oncology

Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC

AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.

Alembic gets USFDA final approval for ANDA Docetaxel Injection

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI

Merck and AstraZeneca present final results from Phase 3 PROpel Trial

Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival